Peer Review channel feed

Af­ter sev­en months of search­ing, Lan­dos hires a CEO; Mar­ty Du­vall re-emerges from ill-fat­ed On­copep­tides tenure

3 years ago

As law­suit car­ries on against Guardant Health, CFO shake­up hits Il­lu­mi­na; Pfiz­er-backed biotech taps CEO to lead pur­suit of gene ther­a­py 2.0

3 years ago

Amarin fish­es for an­oth­er CFO as down­siz­ing takes hold; Cure­Vac makes a deal, then lines up No­var­tis ex­ec to lead de­vel­op­ment

3 years ago

Time Pas­sages: Bruce Gold­smith out at Jim Wilson's gene ther­a­py biotech; Flag­ship re­veals Michael Sev­eri­no’s CEO gig

3 years ago

Al­ways chas­ing the newest sci­ence, Schond Green­way joins MindMed; Mi­rati fills key va­can­cy with ex-Are­na fi­nance chief

3 years ago

Ex-Take­da ex­ec hits the ground run­ning at the helm of rare dis­ease biotech — with 3 pri­or­i­ties off the bat; Sea­soned CEO jumps to ALS up­start

3 years ago

Hel­lo, I must be go­ing: Jorge Gomez is Mod­er­na CFO for on­ly a day; As set­backs mount, In­ovio’s Joseph Kim choos­es the ex­it ramp

3 years ago

With Aduhelm in tat­ters, the search is on for Michel Vounatsos' re­place­ment at Bio­gen; David Liu, Roger Perl­mut­ter join in­sitro's SAB

4 years ago

‘Nat­ur­al evo­lu­tion’: Caris­ma’s sci­en­tif­ic co-founder moves in­to the CSO post; Vas Narasimhan en­lists Ron­ny Gal to help with No­var­tis re­vamp

4 years ago

Mov­ing on from Us­ama Ma­lik's in­sid­er trad­ing im­broglio, Fore re­sets at the top; Take­da spin­out turns to Neu­rana CEO to lead the way

4 years ago

Let’s build some­thing to­geth­er: Ex-Lowe’s CFO to join Pfiz­er while Mod­er­na’s David Meline re­tires; The CEO-part­ner par­ty rolls on at Flag­ship

4 years ago

Xeno­trans­plant gene ed­i­tor eGe­n­e­sis snags trans­plant ex­pert as CMO; John Tsai, Su­sanne Schaf­fert among the hard cuts made at No­var­tis

4 years ago

Changes in high-rank­ing ex­ecs poised to deep­en at Karyopharm; Till­man Gern­gross-chaired biotech pro­motes new med­ical chief to CEO

4 years ago

Roger Perl­mut­ter lures Roy Baynes away from Mer­ck; Now, Voy­ager: Al San­drock be­comes a CEO af­ter break from Bio­gen

4 years ago

Zai Lab gives Josh Smi­ley a sec­ond chance in a prime role; De­nali gets ready to re­arrange staff as clin­i­cal hold con­tin­ues

4 years ago

Centes­sa gives An­toine Yver a new role, brings his old col­league on board; Pre­lude to a change: Jane Huang sets up her next move

4 years ago

Ex­clu­sive: GV’s first net­work de­vel­op­ment part­ner com­pletes ‘full cir­cle’; Just when En­zy­vant scores an ap­proval, Rachelle Jacques plans her ex­it

4 years ago

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ther­a­py ex­ec from No­var­tis

4 years ago

Am­gen, Ipsen vet moves up the lad­der with Co­herus' an­ti-PD-1 await­ing PDU­FA; It takes a vil­lage to re­place Frank Clyburn at Mer­ck­'s Hu­man Health busi­ness

4 years ago

With sotro­vimab in the bal­ance, Bio­gen vet re­unites with George Scan­gos at Vir; First woman to chair PhRMA has more in store at Take­da

4 years ago

Lyell CSO: New job is 'the miss­ing piece' of his ca­reer; Or­p­hazyme and Cor­texyme and Sio, oh my: Your guide to the lat­est CEO changes

4 years ago

Blue­print Med­i­cines gets more ducks in a row be­fore CEO tran­si­tion; Paul Stof­fels has his work cut out for him at Gilead’s crum­bling part­ner

4 years ago

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er leap for­ward at Mer­ck KGaA

4 years ago

Er­ic Os­tertag reach­ing the end of the line as Po­sei­da chief, will be­come ex­ec­u­tive chair­man; Alec­tor ex­ec named CEO of Pfiz­er-backed LNP biotech

4 years ago
First page Previous page 45678910 Next page Last page
A service from the Financial Times